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Abstract
Expression of the phosphatase of regenerating liver-3 (PRL-3) is known to promote tumor growth in gastrointestinal adenocar-
cinomas, and the incidence of tumor formation upon inflammatory events correlates with PRL-3 levels in mouse models. These
carcinomas and their onset are associated with the impairment of intestinal cell homeostasis, which is regulated by a balanced
number of Paneth cells and Lgr5 expressing intestinal stem cells (Lgr5+ ISCs). Nevertheless, the consequences of PRL-3
overexpression on cellular homeostasis and ISC fitness in vivo are unexplored. Here, we employ a doxycycline-inducible
PRL-3 mouse strain to show that aberrant PRL-3 expression within a non-cancerous background leads to the death of Lgr5+
ISCs and to Paneth cell expansion. A higher dose of PRL-3, resulting from homozygous expression, led to mice dying early. A
primary 3D intestinal culture model obtained from these mice confirmed the loss of Lgr5+ ISCs upon PRL-3 expression. The
impaired intestinal organoid formation was rescued by a PRL inhibitor, providing a functional link to the observed phenotypes.
These results demonstrate that elevated PRL-3 phosphatase activity in healthy intestinal epithelium impairs intestinal cell
homeostasis, which correlates this cellular mechanism of tumor onset with PRL-3-mediated higher susceptibility to tumor
formation upon inflammatory or mutational events.
Key messages
• Transgenic mice homozygous for PRL-3 overexpression die early.
• PRL-3 heterozygous mice display disrupted intestinal self-renewal capacity.
• PRL-3 overexpression alone does not induce tumorigenesis in the mouse intestine.
• PRL-3 activity leads to the death of Lgr5+ ISCs and Paneth cell expansion.
• Impairment of cell homeostasis correlates PRL-3 action with tumor onset mechanisms.
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Introduction
PRL-3 (PTP4A3) belongs to the subfamily of the PRL pro-
teins comprising three members (PRL-1, PRL-2, and PRL-3).
While PRL-1 and PRL-2 are expressed in healthy human adult
tissue, PRL-3 is barely found, but it is highly expressed in
primary tumors of different origin and metastases, correlating
with poor outcome [1–3]. PRL-3 activity was shown to pro-
mote tumor growth and metastasis formation in orthotopic
mouse tumor models [4, 5] and also cell migration, invasion,
and epithelial architecture disruption [1, 3, 6–10]. A PTP4A3
knockout mouse model was shown to be grossly normal,
supporting non-essential roles for PRL-3 in healthy tissue
[11]. These mice had a 50% reduced incidence of colon cancer
formation when triggered by inflammation through the
chemotoxins azoxymethane (AOM) and dextran sodium sul-
fate (DSS), reflecting a potential role for PRL-3 in cancer
initiation [11]. In line with this study, a gain-of-function
PRL-3 transgenic (TG) mouse model showed higher inci-
dence of colon malignancy upon DSS treatment [12].
Nevertheless, within the 8 weeks of PRL-3 overexpression
in this mouse model without DSS treatment, no cancer devel-
opment was observed [12]. Whether there are cellular conse-
quences of PRL-3 expression in vivo that could potentially
prime the intestinal tissue for cancer initiation, as suggested
by the results from the DSS-induced inflammation, and
whether the expression of PRL-3 alone over a longer period
of time leads to cancer development have not yet been ad-
dressed. Thus, it is critical to further evaluate the consequence
of PRL-3 expression in a gain-of-function mouse model
system.
Colorectal cancer (CRC) has been associated with the ma-
lignant transformation of intestinal stem cells (ISCs) and ISC
homeostasis failure [13]. The proliferation of ISCs is con-
trolled through Wnt signaling [14–18]. The receptor of R-
spondin Lgr5 is an agonist of Wnt signaling [19, 20] and a
crypt SC marker [21]. Wnt ligands are produced in the crypts
by the epithelial Paneth cells [19], which also require a strong
Wnt signal for their differentiation [14, 22], and the mesen-
chyme, which also produces R-spondin [23]. In the adult in-
testinal epithelium, ISCs are also important for intestinal cell
homoeostasis and for regeneration after a lesion [24, 25]. In
order to accomplish these functions, they replace each other in
a stochastic fashion in order to keep a fixed number of ISCs in
the crypt. As a consequence of this model, ISCs are not long-
lived SCs, and, moreover, the progeny of a single SC is able to
displace all other SCs from the niche [26, 27]. It was hypoth-
esized that cells that have acquired a mutation would be likely
replaced by their neighboring wt ISCs to avoid the fixation of
the mutation. Accordingly, in a cancer background, the reduc-
tion of Lgr5+ ISCs per crypt facilitated the rapid fixation of
Apc tumor suppressor-deficient ISCs in the crypts resulting in
an accelerated tumorigenesis [28]. Dysfunctional or reduced
crypt homeostasis has been accompanied by a decrease in ISC
numbers and Paneth cell expansion. This phenomenon has
been associated with inflammatory bowel disease, with the
administration of the methotrexate rheumatoid arthritis treat-
ment to rats, after intestinal resection, and with the response to
mucosal damage as well as to doxorubicin [14, 29–34].
Considering that (i) inflammatory events affect crypt cell ho-
meostasis, that (ii) reduced renewal capacity of the intestine
contributes to cancer formation, and that (iii) PRL-3 expres-
sion correlates with tumor formation upon inflammatory
events in the intestine, we aim here to answer whether PRL-
3 expression has an influence on crypt homeostasis. To this
end, we generate a doxycycline (dox)-inducible PRL-3 over-
expressing mouse line to investigate the consequences of
PRL-3 overexpression on cellular homeostasis and ISC fitness
in vivo and to answer whether PRL-3 overexpression by itself
causes tumor formation in this system over a longer period of
time.
Results
Homozygous PRL-3 transgenic overexpressing mice
have a short lifespan
To assess the physiological consequences of PRL-3 overex-
pression in vivo, we generated C57BL/6J PRL-3 TG dox-
inducible mice. Unlike the previously reported model [12],
we used a hemagglutinin (HA) tagged human Ptp4a3 cDNA
and introduced it in the collagen type 1 (colA1) locus avoiding
random transgenesis [35]. In this system, the embryonic stem
Fig. 1 Characterization of PRL-3 TG mice (FA1 colony). aWestern blot
analysis of tissue-derived samples from HA-PRL-3 wt/R26-rtTA het
(control) mice treated 15 days with dox and HA-PRL-3 het/R26-rtTA
het (HA-PRL-3 het) mice on dox for 0 (not treated), 2, or 15 days. HA
signal was detected using specific antibodies. Actin was used as a loading
control. HA expression was found in the spleen, skin, colon, and small
intestine. b Anti HA immunohistochemical staining of different tissue
sections derived from control or HA-PRL-3 het mice 15 days on dox.
Scale bar = 100 μm. c Kaplan-Meier survival curve on doxycycline food
for HA-PRL-3 het/R26-rtTA het (PRL-3 het), HA-PRL-3 homo/R26-
rtTA het (PRL-3 homo), and HA-PRL-3 wt/R26-rtTA het (control) mice.
N=10 mice for each genotype. HA-PRL-3 homo mice show a shorter
lifespan compared with control and HA-PRL-3 het mice. d Body weight
split by gender N=4 for male andN=6 for females for each genotype. HA-
PRL-3 wt/R26-rtTA het (control) and HA-PRL-3 het/R26-rtTA het (HA-
PRL-3 het) mice, fed with dox for 12 months, show no differences in
body weight (g=grams). Data represents mean ± s.d., differences non-
significant (ns) with one-way ANOVA with Tukey’s multiple compari-
son test. eWeight measurements (in grams) of PRL-3 homo, PRL-3 het,
and control mice 2 weeks on dox food showed a decrease in the weight of
HA-PRL-3 homo compared to control and HA-PRL-3 het mice. Data
represent mean ± s.d. N=5. *P≤0.1, ***P≤0.001 ordinary two-way
ANOVA with Tukey’s multiple comparison test
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(ES) cells used have been previously engineered to express a
tetracycline-inducible rtTA transactivator driven by the
endogenous Rosa 26 promoter (R26-rtTA) to achieve ubiqui-
tous expression (Fig s1A). Western blot analysis of different
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ES cell clones confirmed the expression of HA-PRL-3 upon
dox addition (Fig s1B and Supp. Material 1). Two HA-PRL-3
independent t ransgenic l ines were obta ined and
characterized—FA1 and FB1 (“Methods” section).
Upon 15 days of dox treatment, PRL-3 mRNA was detect-
ed in all the tested organs derived from bi-transgenic R26-
rtTA and HA-PRL-3 heterozygous (het) mice (Fig s1C).
Moreover, PRL-3 overexpression was strongly detected in
colon, small intestine (SI), spleen, and skin by western blot-
ting in a time-dependent manner, but not in all other organs
tested (Fig. 1a, Fig s1D and Supp. Material 1). Mice contain-
ing only one transgene, either HA-PRL-3 or R26-rtTA, were
used as controls. Immunohistochemical staining validated
PRL-3 expression in those organs and also found small pop-
ulations of cells expressing PRL-3 in the kidney, lung, and
heart (Fig. 1b).
Heterozygous bi-transgenic HA-PRL-3 het/R26-rtTA het
mice did not exhibit evident developmental defects, structural
abnormalities, lifespan variation, differences in body as well
as organ weight, or tumor development after 12months of dox
treatment neither in FA1 (Fig. 1c, d and Fig s1E, F) nor in FB1
(Fig s1G, H, I) compared to the HA-PRL-3 wt/R26-rtTA het
control mice. Given the identical results for both transgenic
lines, the following studies were carried forward using the
FA1 transgenic line. Interestingly, the HA-PRL-3 insertion
in homozygosis (HA-PRL-3 homo) led to a shorter lifespan
(15–30 days) compared to HA-PRL-3 het and control mice
upon dox treatment (Fig. 1c). Nevertheless, the lifespan was
the same for all three genotypes (PRL-3 wt, het, and homo) in
the absence of dox (Fig s1K) confirming that the observed
phenotype is due to PRL-3 expression and not due to any
alteration in the ColA1 expression. In addition, this short
lifespan observed in HA-PRL-3 homo mice correlated with
a striking decrease in their body weight (Fig. 1e).
HA-PRL-3 aberrant expression leads to a decrease of
Lgr5+ ISCs and an increase of Paneth cell counts in
the intestinal crypts
The epithelium of the SI is a highly proliferative tissue main-
tained by Paneth cells and Lgr5+ ISCs located in the crypts. A
defect of Paneth and ISC homeostasis has been associated
with more sensitiveness to tumor development through easier
fixation of sporadic cancer ISC transformations [28]. Because
the SI mimics the physiology of the colon and it is easier to
handle with respect to ex vivo 3D cell culture systems, for a
better comparison of the in vivo and following in vitro exper-
iments, we focused our attention here on the SI tissue. Thus,
we tested whether PRL-3 overexpression interferes in the self-
renewal ability of intestinal tissue by analyzing cell prolifera-
tion. Intestinal tissue samples derived from control HA-PRL-3
het or HA-PRL-3 homo mice treated up to 7 days with dox
(due to the short lifespan of HA-PRL-3 homo mice) were
stained with the KI67 proliferation marker. As expected, no
proliferation was observed in the villi of any of the mice (Fig.
2a). However, a dramatic decrease in the number of KI67+
cells was observed in the intestinal crypts derived from HA-
PRL-3 homo mice compared to controls, while no significant
differences were seen between HA-PRL-3 het and controls
(Fig. 2a, b). In light of this result, we hypothesized that HA-
PRL-3 overexpression could affect specifically the ISCs,
which sustain intestinal cell proliferation and tissue self-re-
newal, in a dose-dependent manner.
To gain further insights, HA-PRL-3 TG mice were crossed
with Lgr5-EGFP-IRES-CreERT2 knock-in mice [21] to ob-
tain HA-PRL-3/R26-rtTA/Lgr5-EGFP-IRES-CreERT2
(named HA-PRL-3/Lgr5-GFP) mice in order to tag the
Lgr5+ ISCs with GFP. After dox treatment, intestinal biopsies
derived from this new mouse strain were stained for immuno-
fluorescence against HA (for HA-PRL-3 detection) and GFP
(for Lgr5-GFP detection), and the nuclei were stained with
Fig. 2 Characterization of the intestinal crypts of PRL-3 TG mice. a
Representative images of KI67 immunohistochemistry of small intestine
biopsies derived from HA-PRL-3 wt/R26-rtTA het (control), HA-PRL-3
het/R26-rtTA het (HA-PRL-3 het), and HA-PRL-3 homo/R26-rtTA het
(HA-PRL-3 homo) mice fed with dox food for 2 days or 7 days. Scale
bar: 100 μm. b Percentage of KI67-positive cells (relative to total cells
counted) in the intestinal crypts from the different genotypes represented
in (a). 1000 cells were analyzed per tissue sample. Values represent mean
± s.d. of three biological replicates. Statistics: *P≤0.1, **P≤0.01 one-way
ANOVA test with Dunnett’s multiple comparisons, compared to control
mice. c Overexpression of PRL-3 (7 days on dox) leads to a decrease of
Lgr5-GFP-positive cells. Representative IF images of small intestine tis-
sue samples from control/Lgr5-GFP, HA-PRL-3 het/Lgr5-GFP, and HA-
PRL-3 homo/Lgr5-GFP using anti-HA antibody (red) for HA-PRL-3
detection and anti-GFP antibody (green) for Lgr5-GFP detection.
Bottom: individual channels. Scale bar 50 μm. N= 3 for each genotype.
d, e Frequencies of sorted ISC Lgr5-GFP high, progenitors Lgr5-GFP
low, and Paneth cells Lgr5-GFP –/CD24 high/Sidescatter high from the
entire small intestine of control/Lgr5-GFP, HA-PRL-3 het/Lgr5-GFP and
HA-PRL-3 homo/Lgr5-GFPmice, treated with dox 0, 2, or 7 days (d) and
3 or 12 months (e). The statistics are as follows: d ISCs 2 days on dox: *
PRL-3 het vs PRL-3 homo, PRL-3 het vs control ns and ** PRL-3 homo
vs control. Progenitors and Paneth cells 2 days on dox: ns. ISCs 7 days on
dox: PRL-3 het vs PRL-3 homo: ns, * PRL-3 het vs control, ** PRL-3
homo vs control. Progenitors 7 days on dox: ns between PRL-3 homo, het
and control. Paneth cells 7 days on dox: *** PRL-3 het vs control,
**PRL-3 homo vs control, PRL-3 het vs PRL-3 homo ns. e 3 months
on dox PRL-3 het vs control: ISCs ns, progenitors * and Paneth cells **.
12 months on dox PRL-3 het vs control: ISCs, progenitors and Paneth
cells ns. Bars represent mean ± s.d. of four biological replicates. ns, not
significant; *P≤0.1,**P≤0.01,***P≤0.001; ordinary two-tailed one-way
ANOVAwith Tukey’s multiple comparison test. f Representative images
of KI67 staining of small intestine biopsies from the mice used in (e),
upper panel 3 months dox treated mice, middle panel samples from 12
months dox treated mice and lower panel HA staining for PRL-3 detec-
tion in mice after 12 months on dox food. g Percentage of KI67 positive
cells (relative to total cells counted) in the intestinal crypts in the different
conditions represented in (f). 1000 cells were analyzed per tissue sample.
Values represent mean ± s.d. of three biological replicates. Statistics:
P≤0.1 t-test, compared to control mice
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Hoechst. HA-PRL-3 homo/Lgr5-GFP showed less Lgr5-GFP
signal compared to intestinal tissue derived from HA-PRL-3
wt and het mice (Fig 2c), suggesting that PRL-3 overexpres-
sion leads into the reduction of ISC numbers. This observation
was quantified by flow cytometry (FC) where the amount of
Lgr5+ ISCs derived from the HA-PRL-3 het/Lgr5-GFP was
already significantly decreased upon dox treatment compared
to those derived from HA-PRL-3 wt/Lgr5-GFP control mice
(Fig. 2d). Interestingly, when HA-PRL-3 was present in ho-
mozygosis, the Lgr5+ ISCs were almost all depleted, suggest-
ing that PRL-3 impairs ISC numbers in a dose-dependent
manner and, consequently, explaining the reduced lifespan
of the homozygous mice. To this end, we confirmed the
higher expression of HA-PRL-3 in homozygous compared
to heterozygous mice in SI tissue by western blot (Fig S2A,
B and Supp. Material 1). Previously, van Es et al. showed that
the decrease of Lgr5+ ISCs in intestinal crypts was linked to
an increase of Paneth cells [22]. In line with this, we also
observed that the decrease in Lgr5+ ISC cells upon PRL-3
overexpression correlated with increased number of Paneth
cells after 7 days of dox treatment (Fig. 2d).
Next, we investigated the long-term consequences of PRL-
3 overexpression in the intestinal epithelium. We measured
the different crypt cell populations by FC in intestine samples
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from mice treated for 3 or 12 months with dox. HA-PRL-3
homo mice were not possible to evaluate under these condi-
tions due to their short lifespan. Keeping the tendency ob-
served at 7 days on dox, the number of Paneth cells was
increased in HA-PRL-3 het/Lgr5-GFP mice after 3 months,
while ISCs kept the same proportion as after 7 days on dox
(Fig. 2e). We hypothesized that the Paneth cell numbers
were increased in order to compensate for the mild decrease
in ISC numbers observed in the HA-PRL-3 het mice, taking
over their role as proliferative cells early on. After 12months
on dox, the number of ISCs in HA-PRL-3 het/Lgr5-GFP
mice was constant compared to the number after 3 months
and again lower than for the control mice. The Paneth cell
number was reduced in HA-PRL-3 het compared to earlier
time points but still slightly higher than in the control popu-
lation. At this time point, the organismmight have adapted to
the lower ISC numbers, reducing the number of Paneth cells
compared to earlier time points. This could explain why the
heterozygous mice survived longer than the homozygous,
where the ISCs were almost depleted already at 7 days on
dox, not giving the Paneth cells enough time for the com-
pensation. In line with the Paneth cells early taking over the
proliferative role and the later organismal adaptation, no dif-
ferences were found in the proportion of proliferative cells
(KI67+) in intestinal biopsies derived from the mice used in
Fig. 2e by KI67 immunohistochemical staining (Fig. 2f, g;
see Fig. S2C, D for colon tissue confirming a similar
phenotype), even though HA-PRL-3 expression was con-
firmed after 12 months of dox treatment (Fig. 2f).
Altogether, this shows that HA-PRL-3 overexpression in
heterozygosis in vivo led to a decrease of Lgr5+ ISCs, which
was likely compensated by increasing the Paneth cell numbers
to maintain intestinal cell homeostasis and stemness. The phe-
notype observed in the intestinal epithelium is PRL-3 dose-
dependent since homozygous HA-PRL-3 mice have
completely lost all the Lgr5+ ISCs, likely leading to the early
death of these mice.
PRL-3 overexpression leads to aberrant intestinal
organoid formation
To better understand the consequences of high PRL-3 levels
in vivo, we used the capacity of ISC-containing epithelial
crypts to form clonogenic organoids [36, 37] as an in vitro
assay of intestinal self-renewal potential. To this end, isolated
crypts from untreated HA-PRL-3 het/R26-rtTA mice were
cultured embedded in extracellular matrix (see “Methods”),
and PRL-3 expression was then induced in vitro at two differ-
ent time points: at the moment of the cell seeding (early in-
duction) in order to analyze the effect of HA-PRL-3 overex-
pression in tissue development and 2 days after seeding (late
induction) when the organoids are already formed, to mimic
the overexpression of PRL-3 in an adult intestine.
Interestingly, organoids failed to form when PRL-3 overex-
pression was early induced (Fig. 3a, b), implicating that PRL-
3 expression is toxic for Lgr5+ SCs, which are the basis for the
development of intestinal organoids [37]. Furthermore, when
PRL-3 expression was induced 2 days after seeding of the
organoids (late induction), they were transformed into aber-
rant intestinal organoids lacking the crypt-like domain
(branches) where ISCs reside (Fig. 3a right panel and Fig.
3c). This phenotype was the same in organoids derived from
the SI of homo HA-PRL-3 expressing mice and was also
identical in organoids derived from colon of HA-PRL homo
and het mice (Fig S3A, B). Furthermore, we confirmed by
western blot that under these conditions, HA-PRL-3 was
expressed in organoids derived from SI and colon, with higher
expression in HA-PRL-3 homo organoids (Fig S3C-F and
Supp. Material 1). These results reflect the strong phenotype
of HA-PRL-3 homozygous expression in vivo.
Subsequently, we investigated whether the observed phe-
notype in the intestinal organoids upon PRL-3 overexpression
was due to its phosphatase activity. With this aim, PRL-3
overexpressing organoids were cultured in presence of analog
3 (A3), a PRL inhibitor that was shown to be active and non-
toxic in 3D cell cultures of laboratory cell lines [9, 38]. The
Fig. 3 PRL-3 overexpression leads to aberrant intestinal organoid
formation. a Representative bright field inverted microscopy images of
small intestinal 3D cell cultures derived from HA-PRL-3 wt/R26-rtTA
het control mice and HA-PRL-3 het/R26-rtTA het mice. HA-PRL-3 ex-
pression was induced in vitro with 1μg/mL of dox. First column: no dox
treatment (never induced); second column: dox was added in the media at
the same time of the cell seeding (early induction); and third column: dox
was added 2 days after cell seeding when the organoids were already
formed (late induction). Pictures were taken after 4 days in culture for
all conditions. Scale bar: 100μm. b Percentage of organoids developed in
each condition at early induction of PRL-3 overexpression relative to the
never induced control. c Percentage of normal organoids with branches,
developed after late induction of PRL-3 overexpression calculated rela-
tive to the total number of organoids developed in each condition. d
Selected bright field inverted microscopy images of the small intestinal
organoids derived from HA-PRL-3 het mice never induced or late in-
duced with dox, after 4 days in culture, treated with DMSO or with
50 μM of analog 3, a PRL phosphatase inhibitor, which was added to
the culture media at the same time as dox. e Percentage of organoids
developed for each condition in (d) at early HA-PRL-3 induction, calcu-
lated relative to the number of organoids developed in the control never
induced with DMSO treatment. f percentage of organoids with branches
for each condition in (d) at late induction calculated relative to the total
organoids. b, c, e, fData are mean ± s.d. N=3. ns not significant, *P≤0. 1,
****P≤0.0001, ordinary two-tailed one-way ANOVAwith Tukey's mul-
tiple comparison test. G Representative bright field inverted microscopy
images of small intestine organoids from HA-PRL-3 het mice, never
induced as control or late induced (after 2 days in culture). Pictures were
taken after 2, 5 or 12 days of dox treatment. Scale bar: 200 μm. h
Representation of the average area of the HA-PRL-3 het organoids +/-
dox shown in (g), as well as of wt organoids +/- dox as control (images
not shown). Values represent the mean ± s.d. N=75. **P≤0.01,




inhibitor was added at the same time as dox to inhibit PRL
activity in parallel to PRL-3 overexpression in order to avoid
residual phosphatase activity. As expected from the results in
Fig. 3a–c, DMSO-treated organoids failed to form when HA-
PRL-3 expression was early induced with dox and showed a
round shape when HA-PRL-3 expression was induced after 2
days of seeding (late induction) (Fig. 3d–f). However, when
these organoids were treated together with A3, the percentage
of formed organoids at early HA-PRL-3 induction increased
(Fig. 3d, e), as did the percentage of organoids with branches
for the late induction (Fig. 3d, f). A3 treatment alone in
uninduced organoids appeared to be mildly cytotoxic in early
induced (Fig. 3e) but not in late induced (Fig. 3f) organoids.
Together, these results confirmed that the observed phenotype
depended on PRL-3 phosphatase activity.
This characteristic phenotype can be due to a morphologi-
cal transformation of the epithelial structure or due to the death
of the Lgr5+ ISCs (located in the branches). In order to discern
between these two possibilities, the area of these cultures after
late induction was monitored over 12 days. As shown in Fig.
3g, h, PRL-3 overexpressing organoids (HA-PRL-3 het/R26-
rtTA het) were not able to grow further upon dox treatment
compared to the never induced or the HA-PRL-3 wt/R26-
rtTA het control organoids treated or not with dox, suggesting
that PRL-3 overexpression provoked organoid death. This
result was validated by a cell viability propidium iodide (PI)
assay where HA-PRL-3 overexpressing intestinal organoids
showed less live cells compared to controls where PRL-3
was not expressed (Fig S4A). Taken together, these results
correlate with the failure in organoid formation when HA-
PRL-3 overexpression was induced at an earlier stage.
PRL-3 overexpression leads to the death of ISCs
To further verify that PRL-3 overexpression triggers the death
of the ISCs selectively, crypts from HA-PRL-3/Lgr5-GFP
mice were isolated and cultured in 3D for 2 days without the
induction of PRL-3 expression leading to fully developed
organoids. Then, HA-PRL-3 overexpression was induced for
the next 2 days (late induction). These organoids showed the
same round-shaped phenotype that was previously observed
for derived intestinal organoids of the bi-transgenic mice (Fig.
3). Indeed, a strong decrease in Lgr5+ cells was observed (Fig.
4a, b), confirming that PRL-3 overexpression is also toxic for
the ISCs in vitro. Moreover, the decrease observed in Lgr5+
cells correlates with a qualitative decrease of proliferative
(KI67+) cells (Fig. 4a), which can explain the failure in
organoid development after PRL-3 expression. This very
strong and fast effect in vitro suggests that like in HA-PRL-
3 homomice in vivo, Paneth cells were not able to compensate
for the reduction of ISCs.
Since some proliferative cells were detected in all
organoids expressing PRL-3 (Fig. 4a and Fig S4B), we
wondered whether any organoid could escape from the
PRL-3-dependent toxicity, surviving and still being able to
proliferate. To address this question, first a dox wash out ex-
periment was carried out. Organoids derived from bi-
transgenic mice (HA-PRL-3 het/R26-rtTA het) were grown
for 2 days, and then PRL-3 overexpression was induced for
2 more days (late induction) by the addition of dox. As control
the same organoids without dox treatment were used (never
induced). The organoids expressing PRL-3 showed the round-
shaped phenotype previously observed. Then these organoids
were grown in dox-free media for 2 more days. Although dox
was removed from the media, no rescue was observed (Fig S4
C, D), and the organoids showed the round-shaped phenotype
confirming that the ISCs in the PRL-3 overexpressing
organoids were compromised and had lost the ability to de-
velop again the crypt-like domain. Second, a reseeding exper-
iment was carried out. Crypts derived from HA-PRL-3 wt/
R26-rtTA het, control, or HA-PRL-3 het/R26-rtTA het
organoids treated or not with dox were trypsinized to single
cells and seeded again in 3D (second seeding). Contrary to the
control, the organoids derived from the PRL-3 overexpressing
aberrant round-shaped organoids were not able to build new
3D structures in the second seeding, not even in the absence of
dox (Fig. 4c, d), demonstrating that the primary organoids
have lost their stemness capacity.
Discussion
Expression and action of PRL-3 phosphatase are associated
with malignant behavior in tumor progression and metastasis.
Here, we generated an inducible PRL-3 transgenic mouse
model to conditionally overexpress human PRL-3 to mimic
conditions observed in patients as close as possible. This new
model has the advantage of introducing one single copy of the
transgene in the colA1 locus, avoiding random integration
[35]. Although PRL-3 mRNA was found in all the tissues
tested, PRL-3 protein expression was only detected in a subset
of tissues, confirming previous results observed for the pTET-
on-pTRE2-Ptp4a3 TG mice [12]. This phenomenon is likely
due to the post-transcriptional regulation of PRL-3 protein, for
which a number of studies have described possible mecha-
nisms [39].
PRL-3 heterozygous overexpression was not sufficient to
induce tumor development in mice even after 12 months of
induction. However, we show that its expression reduces the
population of Lgr5+ ISCs. This phenomenon has been previ-
ously associated with a more rapid fixation of Apc-defective
ISCs within the intestinal crypt leading to an accelerated tu-
morigenesis [28]. Therefore, these observations suggest that
PRL-3 could facilitate tumor initiation and development in the
long run, upon additional—possibly environmental—hits.
Accordingly, PRL-3 KO mice treated with AOM combined
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with DSS exhibited less tumors compared to wt mice [11], and
Lian et al. showed that PRL-3 overexpressing TGmice devel-
oped more tumors compared to wt mice under DSS treatment
[12]. Since DSS is a pro-inflammatory treatment, it can be
presumed that PRL-3 could be involved in inflammation-
related colon malignancy. Consistently, we found that the
amount of Paneth cells increases in intestinal crypts upon
PRL-3 overexpression, which has been associated with in-
flammatory bowel disease developed after intestinal injury
[29–33]. These data together suggest that PRL-3 expression,
by itself, is not sufficient to develop tumors in this system but
that it primes the intestinal tissue for cancer initiation.
When comparing HA-PRL-3 heterozygous mice (on dox)
to control mice, no difference in body weight was observed.
However, in contrast, HA-PRL-3 homozygousmice showed a
dramatic reduction in body weight after 2 weeks of dox treat-
ment together with a short lifespan, indicative of a heavily
compromised gut function, which we observed in histological
and IF staining as well as by flow cytometric quantification of
the crypt composition (Fig. 2a–d). These observations are
likely due to the ablation of the ISCs after 7 days of induction
in HA-PRL-3 homozygous mice compared to a milder reduc-
tion of the population of these Lgr5+ cells observed in the
heterozygous mice. Nevertheless, although our data points
Fig. 4 Overexpression of PRL-3 leads to the death of ISCs. a
Representative confocal microscopy images of IF in small intestinal
organoids derived from HA-PRL-3 wt/Lgr5-GFP (control) or HA-PRL-
3 het/Lgr5-GFPmice never induced or late induced with dox. IF with HA
(red) and KI67 proliferation marker (magenta) antibodies. GFP (green)
native marks the Lgr5 positive cells. Scale bar: 100 μm. b Percentage of
Lgr5-GFP positive organoids observed in (a). c Representative bright
field inverted microscopy images of the small intestinal organoids derived
from control or HA-PRL-3 het mice late induced or without dox (never
induced). After 4 days on dox the cultures were split and reseeded in new
fresh Matrigel, then treated or not with 1 μg/mL dox for 5 more days.
Scale bars: 100μm (d) Representation of the number of secondary
organoids per well, obtained after the reseeding. On the x-axis the geno-
types for the primary derived organoids are represented and +/- corre-
sponds to the dox treatment of the secondary organoids. b, d Data are
mean ± s.d. N=3, **P≤0.01, ****P≤0.0001, ordinary two-tailed two-way
ANOVA with Tukey’s multiple comparison test
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toward the early death of homozygous mice being due to the
compromised gut function, we cannot exclude that other PRL-
3-induced organ defects could contribute to the early death.
Taken together, these results suggest a decrease of Lgr5+ ISCs
in a PRL-3 dose-dependent manner.
The decrease in Lgr5+ ISCs observed in the present study
correlated with an increase in Paneth cells counts, in line with
previous reports where the damage of the ISCs led to the
expansion of Paneth cell numbers [40]. This Paneth cell in-
crease could be explained by their role in niche signaling
maintenance [14, 40]. In fact, Paneth cells also have been
suggested to maintain the stemness capacity of intestinal tis-
sue when ISCs were reduced [14, 41]. Nevertheless, the dra-
matic loss of Lgr5+ cells in HA-PRL-3 homomice may be too
fast to differentiate in order to increase the Paneth cell popu-
lation as much as in the HA-PRL-3 het mice. Therefore, these
mice would not have enough Paneth cells to support the lack
of Lgr5+ ISCs explaining their early death. In line with this
hypothesis, a decrease in KI67+ proliferative cells was also
detected in homozygous mice compared to control or hetero-
zygous mice already after 2 days on dox. Thus, the lack of cell
proliferation and, as a consequence, disruption of intestine cell
homeostasis can explain the early death of the homozygous
mice.
The sensitivity of Lgr5+ ISCs to PRL-3 overexpression
was also confirmed in vitro. Crypts derived from HA-PRL-3
het/R26-rtTA het mice failed to form organoids at early in-
duction and lacked the crypt domain at late induction of PRL-
3 expression. This strong phenotype prevented us from study-
ing differences between the organoids derived from the ho-
mozygous and heterozygous PRL-3 expressing mice, as the
former showed the same phenotype. The complete depletion
of ISCs in the PRL-3 heterozygous organoids wasmuch stron-
ger than the mild reduction of Lgr5+ ISC counts observed
in vivo. This discrepancy could be due to a more complex
in vivo intestine cell homeostasis regulation that could coun-
terbalance the toxic effect of PRL-3 on the intestinal crypts
[24, 25].
Mechanistically, PRL-3 is known for its pleiotropic effects
[1, 10, 12], and therefore it is highly challenging to elucidate
which particular PRL-3-mediated processes cause ISC toxic-
ity. In addition, the severe impact of PRL-3 expression on
organoid formation and the resulting very short life of these
cultures makes the use of intestinal organoids to study the
molecular mechanisms of PRL-3 technically not feasible.
Thus, future in vivo studies will have to shed light on the
mechanisms involved.
In summary, we provide here insights into the cellular con-
sequences of PRL-3 expression in intestinal tissue in vivo.
Our data indicate that PRL-3 expression limits the self-
renewal capacity of the intestine by leading to the death of
ISCs. This reduction can in turn lessen the ability of the intes-
tine to heal itself, making it more prone to inflammation and
cancer initiation [28–33], thus suggesting PRL-3 as a new
therapeutic opportunity for cancer prevention by inhibiting it
at the stage of (chronic) inflammation.
Methods
Plasmids
Human PRL-3 cDNA was amplified with the following
primers including HA in the forward and EcoRI restriction





HA-PRL-3 was cloned with EcoRI into the pgk-ATG-frt-
SAdpA-tetO vector (pBS31).
Generation of HA-PRL-3/R26-rtTA transgenic mice
Fifty micrograms of a plasmid containing the HA-PRL-3 hu-
man cDNA under the control of the doxycycline (dox) respon-
sive promoter (tetO) (see plasmids) was inserted downstream
of the Col1A1 locus (Fig s1A) by co-electroporation with
25 μg of a Flpe recombinase containing vector into KH2-ES
cells [35]. After ES cell electroporation, three positive clones
were able to grow in presence of 150 μg/mL hygromycin.
These clones (A1, B1, and B2) were expanded, and HA-
PRL-3 protein expression was checked by western blot after
dox treatment with anti HA mouse primary antibody (Roche)
(Fig s1B and Sup1). Subsequently, clones A1 and B1 were
independently microinjected into blastocysts fertilized
C57BL/6J embryos. Thus, two bi-transgenic (HA-PRL-3
het/R26-rtTA het) mice from these two independent litters
were used to expand the two TG mouse colonies separately,
corresponding to founders A1 and B1. In order to discard
possible random transgenesis, the phenotype of each mouse
colony was independently analyzed, and the same phenotype
was observed in both.
Animal husbandry and genotyping
HA-PRL-3/R26-rtTA and Lgr5-EGFP-IRES-CreERT2 [21]
mice were kept in pathogen-free housing at EMBL-Rome
and EMBL-Heidelberg, with ethical approval from the corre-
sponding Animal Welfare and Ethical Review Bodies and
national and European legislations. Mice with different com-
binations of theHA-PRL-3 and R26-rtTA alleles were fed with
625 ppm doxycycline-impregnated food in order to achieve
ubiquitous transgene expression and evaluate HA-PRL-3 ex-
pression tolerance. Tail DNA for genotyping was obtained via
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incubation in 200 μL 0.05M NaOH at 98 °C for 1.5 h and
subsequent neutralization with 20 μL 1M Tris HCl pH 7.5.
Mice were genotyped using DreamTaq DNA polymerase
from Thermo Fisher (EP0701) with the following primers (5′-
3′) and PCR programs:
R26-r tTA: AAAGTCGCTCTGAGTTGTTAT;
G G A G C G G G A G A A A T G G A T A T G a n d
GCGAAGAGTTTGTCCTCAACC and PCR program:
95°C × 5 min; [94°C× 30 s; 60°C× 1 min; 72°C ×1.5
min] × 28 cycles; 72oC × 5min
HA-PRL-3: GCACAGCATTGCGGACATGC;
CCCTCCATGTGTGACCAAGG and GCAGAAGC
GCGGCCGTCTGG and PCR program: 94°C × 2 min;
[94°C× 15 s; 60°C× 30 s; 72°C ×30 s] × 29 cycles; 72°C
× 1min
Lgr5-GFP: CACTGCATTCTAGTTGTGG and
CGGTGCCCGCAGCGAG and PCR program: 95°C ×
1 min; [95°C× 15 s; 64°C× 15 s; 72°C ×1.5 min] × 2
cycles; [95°C× 15 s; 61°C× 15 s; 72°C ×1.5 min] × 2
cycles; [95°C× 15 s; 58°C× 15 s; 72°C ×1.5 min] × 23
cycles; [95°C× 15 s; 55°C× 15 s; 72°C ×1.5 min] × 18
cycles; 72°C × 10 min
RNA analysis
For RNA analysis, snap frozen tissues were homogenized
using mortar and pestle while maintaining temperature at
−80 °C using dry ice. RNA extraction was carried out follow-
ing manufacturer’s recommendations (RNeasy Mini Kit,
Qiagen). RNA was treated with DNaseI (Roche) to eliminate
any contaminating DNA. PRL-3 mRNA level was determined
by performing one-step reverse transcription-PCR (Qiagen)
according to the manufacturer’s instructions and using the
primers (5′-3′): forward (GATTACGCTGCTCGGATGAA
C) annealing in HA and reverse (TTCCACTACCTTGC
CGGGC) annealing in PRL-3 sequence; and the PCR pro-
gram: 95°C × 2 min; [95°C× 30 s; 58°C× 45 s; 72°C ×45 s]
× 30 cycles; 72°C × 5min.
Protein analysis
For protein extraction and immunoblots, mouse tissues or
organoids were lysed on ice in RIPA lysis buffer (50mM
Tris HCl pH 7,4, 150 mM NaCl, 1% NP40, 0,25% sodium
deoxycholate) containing complete protease inhibitors
(Roche). For organoids beforehand, lysis Matrigel was re-
moved using cell recovery solution (Corning) as described
in manufacturer’s protocol. Samples were then boiled for
10 min and cleared by centrifugation. Equal amounts of lysate
protein were separated performing SDS-PAGE. Western blot-
ting was performed with anti HA mouse primary antibody
(Roche) and anti actin rabbit primary antibody (SIGMA)
and then with secondary anti-mouse or anti-rabbit antibodies
conjugated to horseradish peroxidase (Sigma and Amersham
Biosciences, respectively). Visualization was achieved with
the Western Lightning Plus-ECL solution (PerkinElmer).
Immunohistochemistry
For immunohistochemical staining, formalin-fixed paraffin
embedded 5-μm sections derived from different mouse tissues
were used. Following deparaffinization with xylene and rehy-
dration with graded ethanol, antigen retrieval was performed
using 0.09% (v/v) unmasking solution (Vector Labs) for
30 min in a steamer. Inactivation of endogenous peroxidases
was carried out using 3% hydrogen peroxide (Sigma) for 10
min. Primary antibodies used, anti HA mouse (Covance clone
11; MMs-101R), anti ki67 pre-diluted (MEDAC 275R-18)
mouse, and/or anti cleaved caspase-3 rabbit (cell signaling
9664S) were diluted in 10% goat serum (Jackson Immuno)
in TBS-Tween 0.1%. Secondary antibody staining and biotin-
streptavidin incubation were performed using species-specific
VECTASTAIN Elite ABC kits (Vector Labs). DAB
Peroxidase Substrate kit (Vector Labs) was utilized for anti-
body detection. Eosin Y and hematoxylin were from Bio-
Optica and Vector Labs. Tissue pictures were obtained using
Tissue tek. Pictures were then analyzed using the QuPath soft-
ware from https://qupath.github.io/.
Immunofluorescence
For the immunofluorescence staining of 3D cell cultures, first
the samples were rinsed with phosphate-buffered saline (PBS)
twice and fixed with 4% paraformaldehyde (PFA) for 20 min.
PFA was then quenched with 0.1 M glycine in PBS for 10
min, and then cells were permeabilized with 0.5% Triton X-
100 in PBS for 10 min and blocked with 10% FBS in PBS
with 0.5% Triton X-100 (blocking solution) for 60 min. Then,
samples were incubated with primary antibodies anti HA rat
high affinity (Roche 11867423001), and cleaved caspase-3
rabbit (cell signaling 9664S), or anti KI67 pre-diluted
(MEDAC 275R-18) mouse in blocking solution at 4°C over-
night, followed by washing and incubation with the corre-
sponding secondary Alexa-fluorophore-conjugated antibody
(1/1000, Invitrogen) for 1 h. Rhodamine-conjugated
phalloidin 1:1000 (R415, Invitrogen) and Hoechst 33342
(10 μg/ml) were also used for membrane and nuclei labeling,
respectively. Cell images were acquired at room temperature
on a spinning disc confocal microscope PerkinElmer
UltraView ERS FIJI software (National Institutes of Health).
Contrast or brightness adjustment was applied to the whole
image. In FIJI software, a 50-pixel rolling ball radius was used
to subtract background, and a 1-pixel-radius median filter was
applied.
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For immunofluorescence in intestinal frozen tissue samples
OCT (Tissue Tek) embedded 10-μm tissue sections were
warmed for 30 min and then washed with PBS-Tween 1%
for 15 min. The sections were then blocked with 2% BSA
(SIGMA) and 8% goat serum (Jackson Immuno-research) in
PBS-Tween 0.1% for 1h. Primary antibodies in the blocking
buffer were added to the slides and incubated overnight at 4°C
(HA rat Roche 11867423001 (1:1000) and rabbit anti-GFP
Abcam 6556 (1:1000)). Samples were washed with PBS.
The secondary antibodies were also dissolved in blocking
buffer (Goat anti-Rat IgG (H+L) Alexa Fluor 647 A-21247;
Goat anti-rabbit IgG (H+L) Alexa Fluor 594 A11037;
Hoechst 33342 H3570 (1:1000, respectively) Samples were
washed with PBS and mounted with Fluoromount-G
(eBioScience). Immunofluorescence images were acquired
at room temperature on a Zeiss LSM880 laser scanning con-
focal microscope using a Plan-Apochromat 25×0.8 NA glyc-
erin objective. Images were processed using FIJI software.
Contrast or brightness adjustment was applied. For visualiza-
tion reasons, the brightness of the red HA-PRL-3 signal in the
HA-PRL-3 homo/Lgr5-GFP sample was slightly increased
compared to the HA-PRL-3 het/Lgr5-GFP sample (Fig. 2c).
In FIJI software, a 50-pixel rolling ball radius was used to
subtract background, and a 1-pixel-radius median filter was
applied.
Three-dimensional organotypic assays
As previously reported [37] and briefly summarized here, SIs
or colons were removed, washed with cold PBS not contain-
ing magnesium chloride and calcium (PBS−/−) opened longi-
tudinally, and then cut into 3–5-mm fragments. Pieces were
washed several times with cold PBS−/− until clean, washed
2–3with PBS−/−EDTA (10mM), and incubated on ice for 90
min, gently shaking. Crypts were then mechanically separated
from the connective tissue by more rigorous shaking and then
filtered through a 70-μm mesh into a 50-mL conical tube to
remove villus material and tissue fragments. Isolated crypts
were washed twice with DMEM F12 (Life Technologies
21331-046), 2mM Glutamax (Life Technologies 35050-
061), 10 mM Hepes, and 5mL penicillin/streptomycin and
centrifuged at 1100rpm × 4min at 4°C. The crypts were then
embedded in 100% Matrigel (Corning 356231 growth factor
reduced) at 5–10 crypts per μL and cultured in the IntestiCult
Organoid GrowMedia for mouse (StemCell Technologies) or
used for FC experiments as described below. For the analog
3 experiment, a precoating with 100% Matrigel was carried
out, and the intestinal cells were embedded in 40% Matrigel
instead of 100% to ensure that the inhibitor can reach the
organoids.
The intestinal organoids were grown in the presence of
doxycycline (SIGMA) at the indicated concentration and time
for each experiment and/or in presence of the PRL inhibitor
A3 (Enamine) [38] or in DMSO as a control.
For reseeding, primary organoids in a 24 well plate were
treated with 2μL collagenase (Worthington Biochemical
corp.) and 2μL liberase TM (Roche) for 2h at 37°C. Then
the gel was completely disaggregated mechanically with a
p1000 pipette and collected in a 15-mL tube with warm PBS
-/- followed by 300g × 5-min centrifugation. For single cells,
the pellet containing rest of the gel and the organoids was
washed with warm PBS-/- and then incubated with 0.5% tryp-
sin (Thermo Fisher) at 37°C for 5 min. The trypsin reaction
was stopped with DMEM F12 including 2mM Glutamax,
10 mM Hepes, 5mL penicillin/streptomycin, and 10% fetal
bovine tetracycline free Serum (Peqlab). Cell pellet was col-
lected by centrifugation at 300g × 5 min. The cells were then
resuspended in 1mL of warm IntestiCult media and seed at 5–
10 crypts per μL density (50 μL per well in a 24 well plate)
and embedded in Matrigel as described above.
Viability assay in organoids
Mouse organoid cultures were set as above described. After 4
days of culture, single cells were obtained as described above
for reseeding cultures. The trypsin reaction was stopped with
15mLDMEMF12 including 2mMGlutamax, 10mMHepes,
5mL penicillin/streptomycin and 10% fetal bovine tetracy-
cline free serum, and 7 μL DNaseI (Roche) and incubated at
RT for 7 min. Cells were recuperated by centrifugation at
300 g × 5 min and resuspended in 200 μL of PBS-/-. Then
the cells were passed through a 70-μm cell strainer, and 0.5
μg/mL of propidium Iodide (SIGMA) was added. PI signal
was measured in a BD LSR Fortessa cell analyzer.
Flow cytometry
For ISC isolation, the crypt suspensions were isolated from
the intestine tissue and dissociated to individual cells follow-
ing the described method above for 3D organotypic assays.
The crypt cell pellet was then washed with cold PBS−/− and
centrifuge at 1100 r.p.m 4 min. Then the cells were incubated
with 300 μL of an antibody cocktail comprising anti mouse
CD45-PerCP55 (BD) 1/400, CD31-perCP55 (BD) 1/400 and
Ter119- perCP55 (BD), 1/400 CD24-BV421 (BD) 1/200,
CD117-PECy7 (biolegend) 1/800, and Epcam-PE (BD)
1/200.
After antibody incubation, pellet was washed again with
PBS−/− and resuspended in 300 μL of PBS−/−. Dead cells
were excluded from the analysis with the viability dye 7-AAD
(Thermo Scientific). The different cell populations
conforming the intestinal crypts derived from KH2-HA-
PRL-3/R26 rtTA × Lgr5-EGFP-IRES-CreERT2 were sorted
[52,53] as (a) ISCs as Lgr5- EGFPhi Epcam+CD24low/
−CD31−Ter119−CD45−7-AAD−, (b) progenitor cells as
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EGFPlowEpcam+CD24low/−CD31−Ter119−CD45−7-AAD ,
and (c) Paneth cells as CD24hiSidescatterh iLgr5-
EGFP−Epcam+CD31−Ter119−CD45−7-AAD− and with a
BD FACS Aria TM Fusion sorter and analyzed with
FACSDiva 8.0.1 software.
Statistical analysis
Ordinary two-tailed one- or two-way ANOVA and Tukey’s or
Dunnett’s multiple comparison tests were performed to study
statistical significance: *P≤0.05, **P≤0.01, ***P≤0.001, and
****P≤0.0001. Statistical analysis and graphs were generated
with Prism (GraphPad).
Control samples for in vivo experiments were obtained
from animals containing the transgenes but kept on a normal
diet or HA-PRL-3 wt/R26-rtTA het mice on dox.
Non-induced organoid cultures (without dox) derived from
HA-PRL-3 wt/R26-rtTA het mouse intestine on a normal diet
were considered as controls in the in vitro assays.
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